{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:26:57Z","timestamp":1790447217716,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.prp.2025.156005","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T16:59:37Z","timestamp":1746809977000},"page":"156005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Nanozymes: A novel approach to upgrade atherosclerosis treatment"],"prefix":"10.1016","volume":"271","author":[{"given":"Maryam","family":"Mahjoubin-Tehran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-769X","authenticated-orcid":false,"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Alamahmeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Karav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.prp.2025.156005_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/0115701611282362240409035233","article-title":"Identification of critical genes differentiating stable and unstable atherosclerotic plaques: a bioinformatic and computational analysis","volume":"22","author":"Mahjoubin-Tehran","year":"2024","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"23","key":"10.1016\/j.prp.2025.156005_bib2","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.jacc.2021.04.035","article-title":"The ARIC (atherosclerosis risk in communities) study: JACC focus seminar 3\/8","volume":"77","author":"Wright","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.prp.2025.156005_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s11658-024-00679-2","article-title":"Sphingolipid metabolites involved in the pathogenesis of atherosclerosis: perspectives on sphingolipids in atherosclerosis","volume":"30","author":"Zhao","year":"2025","journal-title":"Cell Mol. Biol. Lett."},{"issue":"6","key":"10.1016\/j.prp.2025.156005_bib4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/CIRCRESAHA.111.256859","article-title":"Role of phospholipid oxidation products in atherosclerosis","volume":"111","author":"Lee","year":"2012","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.prp.2025.156005_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063346","article-title":"Pathophysiology of atherosclerosis","volume":"23","author":"Jebari-Benslaiman","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156005_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153858","article-title":"MiRNA-205\u20135p regulates the ERBB4\/AKT signaling pathway to inhibit the proliferation and migration of HAVSMCs induced by ox-LDL","volume":"233","author":"Huang","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2025.156005_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/714653","article-title":"The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts","volume":"2013","author":"Maiolino","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.prp.2025.156005_bib8","doi-asserted-by":"crossref","first-page":"5245308","DOI":"10.1155\/2020\/5245308","article-title":"Mechanistic Insights into the oxidized low-density lipoprotein-induced atherosclerosis","volume":"2020","author":"Khatana","year":"2020","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.prp.2025.156005_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fcvm.2019.00089","article-title":"Reactive oxygen species (ROS), intimal thickening, and subclinical atherosclerotic disease","volume":"6","author":"Burtenshaw","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.prp.2025.156005_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.freeradbiomed.2019.10.011","article-title":"Role of reactive oxygen species in atherosclerosis: lessons from murine genetic models","volume":"149","author":"Negre-Salvayre","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.prp.2025.156005_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.925923","article-title":"Mechanisms of oxidized LDL-mediated endothelial dysfunction and its consequences for the development of atherosclerosis","volume":"9","author":"Jiang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.prp.2025.156005_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154773","article-title":"Probing the links: long non-coding RNAs and NF-\u03baB signalling in atherosclerosis","volume":"249","author":"Hussain","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"11","key":"10.1016\/j.prp.2025.156005_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32073","article-title":"Macrophage polarisation and inflammatory mechanisms in atherosclerosis: Implications for prevention and treatment","volume":"10","author":"Yang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.prp.2025.156005_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154490","article-title":"NLRP3 inflammasome pathway in atherosclerosis: focusing on the therapeutic potential of non-coding RNAs","volume":"246","author":"Al-Hawary","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"2","key":"10.1016\/j.prp.2025.156005_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/medicina58020299","article-title":"Atherosclerosis development and progression: the role of atherogenic small, dense LDL","volume":"58","author":"Vekic","year":"2022","journal-title":"Medicina"},{"issue":"1","key":"10.1016\/j.prp.2025.156005_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/life11010039","article-title":"LDL-cholesterol and platelets: insights into their interactions in atherosclerosis","volume":"11","author":"G\u0105secka","year":"2021","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.prp.2025.156005_bib17","doi-asserted-by":"crossref","first-page":"20334","DOI":"10.1038\/s41598-022-24260-z","article-title":"In silico and in vitro analysis of microRNAs with therapeutic potential in atherosclerosis","volume":"12","author":"Mahjoubin-Tehran","year":"2022","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.prp.2025.156005_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.001800","article-title":"Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis","volume":"1","author":"Jones","year":"2012","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.prp.2025.156005_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.phrs.2018.08.014","article-title":"Effect of statins on toll-like receptors: a new insight to pleiotropic effects","volume":"135","author":"Bahrami","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.prp.2025.156005_bib20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2016.07.897","article-title":"Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms","volume":"253","author":"Chru\u015bciel","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.prp.2025.156005_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.plipres.2015.08.003","article-title":"Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials","volume":"60","author":"Ferretti","year":"2015","journal-title":"Prog. Lipid Res."},{"issue":"2","key":"10.1016\/j.prp.2025.156005_bib22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jcsm.12654","article-title":"Effects of statins on mitochondrial pathways","volume":"12","author":"Mollazadeh","year":"2021","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/j.prp.2025.156005_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11745-010-3517-x","article-title":"Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial","volume":"46","author":"Parizadeh","year":"2011","journal-title":"Lipids"},{"issue":"2","key":"10.1016\/j.prp.2025.156005_bib24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2015.05.022","article-title":"Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials","volume":"241","author":"Sahebkar","year":"2015","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.prp.2025.156005_bib25","first-page":"546","article-title":"Association between statin use and plasma d-dimer levels: a systematic review and meta-analysis of randomised controlled trials","volume":"114","author":"Sahebkar","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.prp.2025.156005_bib26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1160\/th15-08-0620","article-title":"The impact of statin therapy on plasma levels of von Willebrand factor antigen: systematic review and meta-analysis of randomised placebo-controlled trials","volume":"115","author":"Sahebkar","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.prp.2025.156005_bib27","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00204-023-03492-6","article-title":"Understanding the molecular mechanisms of statin pleiotropic effects","volume":"97","author":"German","year":"2023","journal-title":"Arch. Toxicol."},{"issue":"7","key":"10.1016\/j.prp.2025.156005_bib28","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2025.156005_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.phrs.2015.07.008","article-title":"Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials","volume":"99","author":"Banach","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.prp.2025.156005_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.03.010","article-title":"Mechanisms of statin-associated skeletal muscle-associated symptoms","volume":"154","author":"Bouitbir","year":"2020","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.prp.2025.156005_bib31","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","article-title":"New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes","volume":"35","author":"Sahebkar","year":"2013","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.prp.2025.156005_bib32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10557-013-6479-4","article-title":"New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?","volume":"27","author":"Sahebkar","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"5","key":"10.1016\/j.prp.2025.156005_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40256-023-00594-5","article-title":"Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention","volume":"23","author":"Michaeli","year":"2023","journal-title":"Am. J. Cardiovasc Drugs"},{"issue":"5","key":"10.1016\/j.prp.2025.156005_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11883-021-00918-3","article-title":"Lipid lowering drugs: present status and future developments","volume":"23","author":"Ruscica","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"issue":"2","key":"10.1016\/j.prp.2025.156005_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_20_20","article-title":"PCSK9 monoclonal antibodies: an overview","volume":"21","author":"Kaddoura","year":"2020","journal-title":"Heart Views"},{"issue":"10","key":"10.1016\/j.prp.2025.156005_bib36","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41401-024-01305-9","article-title":"A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis","volume":"45","author":"Wang","year":"2024","journal-title":"Acta Pharm. Sin."},{"issue":"3","key":"10.1016\/j.prp.2025.156005_bib37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S2213-8587(23)00325-X","article-title":"PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial","volume":"12","author":"Koren","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.prp.2025.156005_bib38","first-page":"25","article-title":"Emerging oral therapeutic strategies for inhibiting PCSK9","volume":"59","author":"Ferri","year":"2025","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.prp.2025.156005_bib39","first-page":"S24","article-title":"Efficacy, benefit and safety of inclisiran","volume":"36","author":"Lopez-Miranda","year":"2024","journal-title":"Clin. Invest. Arterioscler."},{"issue":"8","key":"10.1016\/j.prp.2025.156005_bib40","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1021\/acs.accounts.9b00140","article-title":"Nanozymes: from new concepts, mechanisms, and standards to applications","volume":"52","author":"Liang","year":"2019","journal-title":"Acc. Chem. Res."},{"issue":"1","key":"10.1016\/j.prp.2025.156005_bib41","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12951-022-01295-y","article-title":"Nanozymes-recent development and biomedical applications","volume":"20","author":"Ren","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.prp.2025.156005_bib42","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-981-13-9791-2_9","article-title":"Nanozymes: biomedical applications of enzymatic Fe 3 O 4 nanoparticles from in vitro to in vivo","author":"Gao","year":"2019","journal-title":"Biol. Bio-inspired Nanomater. Prop. Assem. Mech."},{"issue":"1","key":"10.1016\/j.prp.2025.156005_bib43","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/s41467-021-22286-x","article-title":"In vivo activation of pH-responsive oxidase-like graphitic nanozymes for selective killing of Helicobacter pylori","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.prp.2025.156005_bib44","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1021\/acs.chemrev.8b00672","article-title":"Nanozymes: classification, catalytic mechanisms, activity regulation, and applications","volume":"119","author":"Huang","year":"2019","journal-title":"Chem. Rev."},{"issue":"5","key":"10.1016\/j.prp.2025.156005_bib45","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41929-021-00609-x","article-title":"Matching the kinetics of natural enzymes with a single-atom iron nanozyme","volume":"4","author":"Ji","year":"2021","journal-title":"Nat. Catal."},{"issue":"9","key":"10.1016\/j.prp.2025.156005_bib46","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1039\/D2TB02661A","article-title":"Engineering ROS-scavenging Prussian blue nanozymes for efficient atherosclerosis nanotherapy","volume":"11","author":"Chen","year":"2023","journal-title":"J. Mater. Chem. B."},{"issue":"8","key":"10.1016\/j.prp.2025.156005_bib47","doi-asserted-by":"crossref","first-page":"10414","DOI":"10.1021\/acsami.2c20492","article-title":"Reduction of reactive oxygen species accumulation using gadolinium-doped ceria for the alleviation of atherosclerosis","volume":"15","author":"Gao","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"15","key":"10.1016\/j.prp.2025.156005_bib48","doi-asserted-by":"crossref","first-page":"14555","DOI":"10.1021\/acsnano.3c01420","article-title":"Design of a multifunctional nanozyme for resolving the proinflammatory plaque microenvironment and attenuating atherosclerosis","volume":"17","author":"He","year":"2023","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.prp.2025.156005_bib49","doi-asserted-by":"crossref","first-page":"15959","DOI":"10.1021\/acsnano.2c03422","article-title":"Living macrophage-delivered tetrapod PdH nanoenzyme for targeted atherosclerosis management by ROS scavenging, hydrogen anti-inflammation, and autophagy activation","volume":"16","author":"Hu","year":"2022","journal-title":"ACS Nano"},{"issue":"33","key":"10.1016\/j.prp.2025.156005_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202304465","article-title":"Integrated cascade nanozymes with antisenescence activities for atherosclerosis therapy","volume":"62","author":"Liu","year":"2023","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"10.1016\/j.prp.2025.156005_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2022.119940","article-title":"Hyaluronic acid-guided assembly of ceria nanozymes as plaque-targeting ROS scavengers for anti-atherosclerotic therapy","volume":"296","author":"Wang","year":"2022","journal-title":"Carbohydr. Polym."},{"issue":"1","key":"10.1016\/j.prp.2025.156005_bib52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12951-023-02276-5","article-title":"NOS-like activity of CeO2 nanozymes contributes to diminishing the vascular plaques","volume":"22","author":"Sun","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.prp.2025.156005_bib53","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1038\/s41467-022-34248-y","article-title":"Small molecule-assisted assembly of multifunctional ceria nanozymes for synergistic treatment of atherosclerosis","volume":"13","author":"Fu","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.prp.2025.156005_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.06.008","article-title":"Enhanced macrophage polarization induced by COX-2 inhibitor-loaded Pd octahedral nanozymes for treatment of atherosclerosis","volume":"34","author":"Xu","year":"2023","journal-title":"Chin. Chem. Lett."},{"issue":"39","key":"10.1016\/j.prp.2025.156005_bib55","doi-asserted-by":"crossref","first-page":"51944","DOI":"10.1021\/acsami.4c08671","article-title":"Novel metal-free nanozyme for targeted imaging and inhibition of atherosclerosis via macrophage autophagy activation to prevent vulnerable plaque formation and rupture","volume":"16","author":"Wang","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825001979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825001979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T02:30:15Z","timestamp":1749004215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825001979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":55,"alternative-id":["S0344033825001979"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156005","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanozymes: A novel approach to upgrade atherosclerosis treatment","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156005"}}